Retatrutide (LY3437943) is a synthetic peptide developed by Eli Lilly that functions as a triple receptor agonist, engaging GLP-1R, GIPR, and GcgR simultaneously. This tri-agonist design distinguishes it from dual agonists such as tirzepatide and selective GLP-1R agonists such as semaglutide.
Triple Receptor Pharmacology Research
Preclinical and clinical pharmacology research has examined retatrutide's differential activity at each of its three target receptors and the additive interactions between GLP-1R, GIPR, and GcgR signaling in experimental metabolic models.
Glucose Homeostasis and Incretin Research
Research has examined retatrutide's interactions with pancreatic beta cell function through GLP-1R and GIPR engagement, including its effects on glucose-stimulated insulin secretion and glucagon suppression in experimental models.
Clinical Research Profile
Retatrutide has progressed through Phase 1 and Phase 2 clinical research. Phase 2 results published in The New England Journal of Medicine examined metabolic outcomes in clinical study participants.
• Jastreboff AM et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine, 389(6), 514–526.
• Urva S et al. (2023). LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist. The Lancet, 402(10401), 526–536.
